{"disease":{"id":"muscular-disorders-atrophic","name":"muscular disorders atrophic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03179631","title":"Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT01826487","title":"Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT02090959","title":"An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":219,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT06289608","title":"Bruxism and Underlying Psichological Factors","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University of Salamanca","has_results":false},{"nct_id":"NCT05479981","title":"Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Avidity Biosciences, Inc.","has_results":false},{"nct_id":"NCT06217835","title":"What Are the Effects of Lower Limb Dysmetria on Gluteus Medius and Erector Spinae Musculature?","phase":"NA","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Camilo Jose Cela University","has_results":false},{"nct_id":"NCT03406780","title":"A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Capricor Inc.","has_results":true},{"nct_id":"NCT05730842","title":"Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Edgewise Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06228742","title":"Molecular Mechanisms Underlying Anabolic Resistance to Protein Intake During Muscle Disuse","phase":"NA","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"United States Army Research Institute of Environmental Medicine","has_results":false},{"nct_id":"NCT07250737","title":"Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Avidity Biosciences, Inc.","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}